CARSGEN Revenue and Competitors
Estimated Revenue & Valuation
- CARSGEN's estimated annual revenue is currently $32.9M per year.
- CARSGEN's estimated revenue per employee is $155,000
Employee Data
- CARSGEN has 212 Employees.
- CARSGEN grew their employee count by -2% last year.
CARSGEN's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-founder, Chairman the Board, CEO, CSO | Reveal Email/Phone |
2 | Co-founder and COO | Reveal Email/Phone |
3 | SVP - Global Regulatory Affairs | Reveal Email/Phone |
4 | Director Clinical Operations and Data Sciences | Reveal Email/Phone |
5 | Clinical Scientist | Reveal Email/Phone |
6 | QC Microbiology Analyst 1 | Reveal Email/Phone |
CARSGEN Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is CARSGEN?
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T and antibody therapeutics. Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the United States. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-Claudin18.2-T for gastric and pancreatic cancer, CAR-GPC3-T for hepatocellular carcinoma (HCC) and squamous lung cancer and CAR-EGFR/EGFRvIII-T for glioblastoma. CARsgen also has ongoing clinical programs with a fully human CAR-BCMA-T for multiple myeloma and a humanized CAR-CD19-T for leukemia. CARsgen's proprietary antibody platform enables the development of therapeutic antibodies. Its leading humanized monoclonal antibody targeting Claudin18.2 has obtained IND approval from the NMPA.
keywords:N/A
N/A
Total Funding
212
Number of Employees
$32.9M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CARSGEN News
CARsgen Therapeutics, Novartis International AG, Pfizer Kite Pharma Legend Biotech, Juno Therapeutics, Aurora Biopharma Inc., Bluebird Bio...
CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment...
A: CARsgen plans to manufacture innovative CAR T cell therapy products in the RTP Manufacturing Facility to support its clinical studies and...
Other Companies in Shanghai
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $33.1M | 215 | 1% | N/A |
#2 | $69M | 228 | 1% | N/A |
#3 | $32.5M | 232 | 5% | N/A |
#4 | $37M | 239 | 1% | N/A |
#5 | $20.8M | 242 | 13% | $22M |